INTRODUCTION
Zinc finger (ZNF) containing proteins are extremely abundant in higher eukaryotes and can function as sequence-specific DNA-binding factors. Following the sequencing of the human genome, genes encoding hundreds of zinc finger proteins have been uncovered, but the functional significance of most is partially or completely unknown. One zinc finger protein that has received recent interest as a potential oncogene is ZNF217. This review will focus on the evidence that selection for ZNF217 expression drives 20q13 amplification in a variety of cancers, and on new molecular studies that have begun to dissect the mechanisms by which ZNF217 amplification may provide selective advantages to cancer cells.
Chromosome 20q13 amplifications in human cancers
DNA amplifications are common in human cancers, can result in increases in gene expression, and are often sites of oncogenes that confer proliferative and/or survival advantages to host cells. Amplifications involving human chromosome 20q13 are observed in a number of different cancer types, including breast [1] [2] [3] , ovarian [4, 5] , and squamous cell cancers [6, 7] . 20q13 amplifications have been shown to be associated with reduced disease-free survival [8, 9] , reduced patient survival [10] , increased mean cell proliferation activity [11] , increased tumour grade/aggressiveness [9, 12] , and to correlate with poor prognosis. 20q13
amplifications are thought to occur early in the course of breast cancer development [13] . The finding that the 20q13 region is selectively targeted for amplification during cancer progression suggests that it contains one or more genes that confer selective advantages to cancer cells. 3 In order to understand the contribution of 20q13 amplification to tumorigenesis, research has focused on defining the minimal common amplified region. In 1994, a 1.5 Mb region was identified in breast cancer cell lines, but at the time no obvious candidate oncogenes within this region were known [14] . However, as information about the human genome has accumulated, a number of genes found on chromosome 20q13 have been identified as possible oncogenic targets of amplification. These include STK15/BTAK/Aurora2 [15] [16] [17] , CAS [18] [19] [20] , BCAS1/NABC1 [21] , PFDN4 [22] , EEF1A2 [23] , CYP24 [24] and ZNF217 [25] [24].
It is likelypossible that there is more than one oncogene in the 20q13.2 amplicon as a case can be madethere is evidence that manyseveral of these genes may contribute towards tumour development. For example, EEF1A2, which encodes a protein elongation factor, has been shown to transform NIH 3T3 fibroblasts and injection of these transformed cells into mice was sufficient tothese transformed cells induced tumours in mice [23, 26] . Similarly, the STK15 gene which encodes the centromere associated kinase Aurora2 has been shown to transform NIH 3T3 fibroblasts and MCF7 breast carcinoma cells [27] . In this review we will focus on the evidence that ZNF217 is an the oncogene ZNF217.
ZNF217 is a candidate oncogene on 20q13.2
In order for a particular gene in an amplicon to be driving the selection of cells with the amplification, this gene must be located at the core of the amplified region and amplification must lead to over-expression of the gene. In 1998, Collins and colleagues [25] [24] cloned a 1 Mb region of chromosome 20q13. They defined ã 260 kb region of maximal amplification that was common to a series of breast tumours and described a new gene, ZNF217, which was found within this 260 kb region. ZNF217 was shown to be more highly expressed in all ten breast cancer cell 4 lines carrying the 20q13 amplification than in lines with normal 20q13 copy number.
This study provided evidence that ZNF217 fits the criteria for a driver gene in the 20q13 amplicon. Compelling support for the hypothesis that ZNF217 can contribute to cancer came from a study which demonstrated that transduction of finite life-span human mammary epithelial cells with ZNF217 gave rise to immortalized cells [36] [33] . This provided the first direct evidence for a potentially oncogenic function of ZNF217. 5 The results suggested that the selective amplification of ZNF217 may allow cancer cells to overcome senescence and become immortal, thought to be a crucial event in the development of many cancers [37] [34] . ZNF217-immortalized cell lines were
shown to have increased telomerase activity and stable telomere lengths,
suggesting that ZNF217 may function, in part, by allowing pre-malignant cells to derepress telomerase and overcome senescence due to telomere dysfunction [36] [33].
In support of this original study, ZNF217 has recently been shown to immortalize ovarian cells [38] [35] . ZNF217 transduction into ovarian surface epithelial cells with extended but finite life-spans, combined with EGF treatment, led to cellular immortalization. Although EGF treatment was necessary during the immortalization process, the permanent lines that were established were able to grow without EGF.
The siRNA mediated knock-down of ZNF217 in these permanent lines led to growth arrest, demonstrating that the continued proliferation was dependent on ZNF217.
ZNF217 transduction also allowed the acquisition of three other malignancy associated characteristics in ovarian surface epithelial cells: reduced serum dependence, anchorage independence and increased telomerase activity.
In addition to the ability to proliferate indefinitely, cancer cells acquire the ability to resist apoptotic signals. 
ZNF217 is a transcription factor
The original paper by Collins and colleagues which identified the ZNF217 gene within the 20q13.2 amplified region noted that ZNF217 contains 8 zinc fingers ( Figure 1 ) and proposed that it functions as a sequence-specific DNA-binding transcription factor [25] [24]. GFP-ZNF217 was later shown to localize to the nuclei in HeLa cells [41] [38] . New research has provided experimental evidence that ZNF217 is indeed a transcription factor, and suggests that ZNF217 amplification may promote cancer through alterations in the regulation of key target genes.
Supporting evidence for the role of ZNF217 as a transcription factor came first from co-immunoprecipitation experiments (Figure 2 ). ZNF217 was found in complexes immunoprecipitated by antibodies to the transcriptional co-repressor CoREST [42] [39], the lysine specific histone demethylase LSD-1 (also known as BHC110) [ CoREST, histone deacetylases HDAC1 and 2, and LSD-1. Three of the complexes also contained CtBP proteins (Figure 2 ). ZNF217 has since been shown to be a Additionally, the site selection assay only detects sites to which ZNF217 binds 9 directly, whereas the ChIP-CHIP assays are also expected to detect sites to which ZNF217 binds indirectly through interactions with other DNA binding proteins. [48] (Figure 1 ). These four models are non-exclusive and their relative contributions could depend on cell and promoter context.
How might ZNF217 influence tumorigenesis?
From the set of promoters that were identified to be bound by ZNF217 in ChIP-CHIP experiments, Krig and colleagues selectedidentified the top 1000 target promoters from the two sets ofbound by ZNF217 in Ntera2 cellls promoter array data (1276 promoters in total) and examined the RNA expression levels of the 1077 of these targets which were represented onusing an expression array [52] . These expression arrays were used to The identificationy of sets of genes associated with expression levels which correlate with ZNF217 expression in vivo allowed an analysis of the processes that ZNF217 is likely to regulate [49] [46]. The majority of 10 th The majority of the top-ranked target genes had low levels of RNA expression, supporting the hypothesis that ZNF217 is a repressor of transcription and is silencing the promoters to which it binds. However, a small subset of the top-ranked target genes had high levels of RNA expression, indicating that ZNF217, like many transcription factors may also act as both an activator and repressor of transcription at some promoters. The promoters that ZNF217 was shown to occupy were categorized and were shown to be associated with proteins involved in processes such as transcriptional regulation, organ development, cell differentiation, cell adhesion, and embryonic development. In further ChIP-CHIP assays, the promoters bound by ZNF217 and CtBP were compared. The majority of ZNF217 targets were also bound by CtBP in both Ntera2 and MCF7 cells, suggesting that these two proteins often co-operate in gene repression. The PR/SET domain in the RIZ protein is indicated by wide grey rectangles.
Putative functional domains are underlined. A scheme is presented of ZNF217-containing transcriptional repressor complexes that have been identified through co-immunoprecipitation experiments.
Components common to all four complexes are highlighted in grey. 
